📉 CLDX $1.1M Long Put Position CLOSED — Bearish Bet Stopped Out as Stock Rallies 25% Above Strike

📅 April 28, 2026 | 🔥 Highly Unusual Activity Detected

---

🎯 The Quick Take

A sophisticated trader just received $1.1 MILLION to close out a previously-opened LONG put position on Celldex Therapeutics — selling to close the $27 strike put expiring December 2026. This was a bearish bet that CLDX would fall below $27, and it has not worked: the stock currently sits at $33.84, roughly 25% above the strike. The trader is exiting their losing bearish position — salvaging $7.40 per contract before the puts decay further — which reads as a capitulation by a bear who got the direction wrong.

---

🏢 Company Overview

Celldex Therapeutics (NASDAQ: CLDX) is a clinical-stage biotechnology company built around the science of mast cell biology. Its lead asset, barzolvolimab, is a humanized monoclonal antibody that targets the KIT receptor on mast cells — the cells that drive the inflammatory cascade behind conditions like chronic hives, cold urticaria, and prurigo nodularis.

• Market Cap: ~$2.5–2.6B (approximately 78 million shares outstanding post-April offering) per companiesmarketcap
• Current Price: $33.84 (April 28, 2026)
• 52-Week Range: $14.40 – $33.84+
• Stage: Clinical-stage, pre-revenue — the company generates essentially no product revenue; it trades on clinical progress
• Cash Position: Pro-forma well above $800M following the April 6, 2026 $345M public offering, up from $518.6M at year-end 2025 per BioSpace
• Primary Catalyst: Phase 3 EMBARQ-CSU1/CSU2 topline readout in chronic spontaneous urticaria (CSU) expected Q4 2026, setting up a potential 2027 BLA filing

CLDX is not a company you evaluate on earnings multiples or cash flow. It is a single-pipeline binary bet. Barzolvolimab either demonstrates statistically significant improvement in UAS7 (Urticaria Activity Score) versus placebo in the Phase 3 trials, or it doesn't. That binary event — likely six to eight months away — is what everything else revolves around.

---

💰 The Option Flow Breakdown

📊 The Tape (April 28, 2026)

🤓 What This Actually Means

This trade is a Sell to Close (STC) on a Long Put — the trader had previously bought the $27 strike December put (paying premium upfront to bet CLDX would fall below $27), and is now selling it back to exit the position. The "SELL" on the tape is closing a net long-put position, not opening a new short.

Real talk: this is a bearish trader stopping out of a losing bet. Here is why:

• 📉 The original thesis was bearish: Buying a $27 put is a bet that CLDX drops below $27 by December 2026. The stock sat at $29.00 during the April 6 offering and has since rallied to $33.84 — moving in exactly the wrong direction for this trader
• 💸 Salvaging what's left: At $7.40 per contract with the stock 25% above the strike, these puts are deeply out-of-the-money. Most of their original time value has eroded. The trader is exiting now to recover $1.1M rather than risk losing more as Theta continues to grind the premium down
• 🎯 Strike is deeply out-of-the-money: At $27 strike with the stock at $33.84, CLDX would need to fall -20.2% just to reach the strike — and another dollar-plus below that to break even on the original purchase
• 📊 Z-score of 2.52 = HIGHLY UNUSUAL: This is 2.52 standard deviations above normal put activity at this strike, flagging institutional-scale positioning — roughly a few times a year occurrence at this contract
• 📅 December expiration context: The December 2026 expiration was chosen to bracket the Q4 2026 EMBARQ-CSU Phase 3 readout. The original bearish buyer was betting CLDX would collapse heading into or after the Phase 3 — perhaps expecting the EoE failure in August 2025 to foreshadow a CSU Phase 3 miss. That thesis has not materialized so far.
• ⚖️ Vol/OI ratio of 1.364: Volume of 1,500 against open interest of 1,100 means the entire existing position in this contract is being closed — a full exit signal

The most likely narrative:

Stopping out a losing bear bet. When this trader originally bought the $27 puts (likely near the April offering, when the stock was around $29–$30), they were betting on a decline back toward or below the offering level. The April offering at $29.00 per share was potentially seen as a ceiling — dilution overhang, insider supply, and the EoE disappointment precedent were reasonable bearish inputs. But CLDX has run nearly +17% since the offering, clinical momentum is building, and analysts are upgrading. The bearish thesis broke down, and this STC is the exit.

An alternative reading — that the trader is locking in profit from a brief CLDX dip after the original purchase — is theoretically possible but unlikely given the 25% rally backdrop. If the stock had crashed to $27 and recovered, we would expect to have seen that in the tape. The cleaner read is a bear who was wrong.

What this is NOT: This is not a short put being bought back. A short put (selling puts for income) would show a Buy to Close (BTC). The Order Type here is STC — Sell to Close — confirming the trader is closing out a previously-owned long put position.

Unusual Score: 🔥 HIGHLY UNUSUAL (2.52 Z-score) with HIGH_ACTIVITY Vol/OI signal — this is a significant institutional-sized capitulation of a prior bearish position.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

CLDX has been on a strong run in 2026. The stock climbed from $14.40 lows (52-week low) toward new multi-year highs above $33 in March–April 2026, fueled by enrollment completion in the EMBARQ-CSU Phase 3 program six months ahead of guidance per Celldex IR and positive AAAAI 2026 conference data.

The April 6 secondary offering at $29.00 created a brief overhang but the stock has already recovered and pushed through the offering price by nearly +17%, suggesting the market is comfortable absorbing the dilution in exchange for an $800M+ cash runway. The bear who bought the $27 puts was betting the offering would be a ceiling, not a springboard — that call has so far been wrong.

Key observations:

• 📈 Strong 2026 YTD momentum: Driven by clinical milestones and analyst upgrades including Barclays moving to Overweight with a $45 PT per Markets Daily
• 📉 April offering dip absorbed: $29 was the dilution floor; current $33.84 is comfortably above it — the offering created a natural entry for fast money, not a distribution event
• 🎯 Critical levels: $29 (offering price) has flipped to support; $32 is the next meaningful gamma support level per the GEX data
• 📊 Biotech pattern: CLDX is accumulating steadily into the Phase 3 readout — the opposite of what the original bearish put buyer expected

Gamma-Based Support & Resistance Analysis

Current Price: $33.84

The gamma exposure map shows where dealer hedging activity creates natural price anchors. For a $2.5B biotech, these levels are thinner than large-cap names but still meaningful.

🔵 Support Levels (Put Gamma Below Current Price):

• $32.00 — Nearest support, 4.96% below current; this is the strongest put gamma concentration on the downside with a net GEX of -0.027 (put-heavy, providing cushion)
• $30.00 — Secondary support at 10.9% below current; thin gamma here but still a round-number psychological anchor
• $29.00 — The offering price level at 13.9% below current; both gamma and behavioral support (offering buyers defend their entry)
• $27.00 — The strike in today's trade, 20.2% below current; significant put gamma concentration (net GEX -0.033) — market makers hold put positions here that create a natural gamma floor in a downside scenario. This is also where the exiting trader's bet was anchored — a level the stock never came close to threatening

🟠 Resistance Levels (Call Gamma Above Current Price):

• $35.00 — STRONGEST RESISTANCE, only 3.95% above current; dominant call GEX of 0.105 makes this the primary ceiling. Market makers short calls here will sell stock as price approaches this level to hedge
• $36.00 — Secondary resistance at 6.9% above; lighter call concentration
• $37.00–$38.00 — Extended resistance zone at 9.9–12.9% above; stepping-stone targets if $35 is breached
• $40.00 — Major call gamma wall at 18.8% above current; this is where significant upside positioning lives

What this means: CLDX is sandwiched between $32 support and $35 resistance — a tight 9% range. The GEX summary shows a bullish net bias (total call GEX of 0.252 vs put GEX of 0.103), meaning dealer positioning overall leans toward supporting the stock on dips. Breaking $35 cleanly opens the path toward $37–$40.

Implied Move Analysis

Options market pricing for upcoming expirations:

• 📅 Monthly OPEX (May 15 — 17 days): ±$2.00 (±5.94%) → Implied range: $31.60 – $35.60

The near-term implied move is modest at roughly 6% in either direction through May 15. This reflects the absence of a major near-term binary catalyst — the Phase 3 readout is not until Q4 2026. The earnings report (expected early May) is the most imminent event and is consistent with a 5–6% options-implied move for a clinical-stage biotech.

Key takeaway: The $35.60 upper bound of the implied range aligns almost exactly with the $35 gamma resistance wall identified above. The $31.60 lower bound sits just below the $32 gamma support level. The options market and the gamma structure are telling the same story — expect CLDX to consolidate in the $31.60–$35.60 range through May OPEX unless a catalyst forces a directional break.

---

🔬 Catalysts

The Context Behind the Original Bearish Bet

Before diving into the forward catalyst calendar, it's worth framing what likely motivated the original long-put purchase. The bearish trader probably looked at:

• The April 6 secondary at $29.00 as a potential ceiling — dilution at $29 after the stock had already run
• The EoE Phase 2 failure in August 2025 — barzolvolimab showed mast cell depletion but no clinical benefit, raising questions about CSU Phase 3 translation
• The Q4 2026 Phase 3 as a potential binary that could wipe out the premium baked into the stock

The $27 strike, chosen well below the offering price, may have reflected a scenario where the Phase 3 narrative frays, the offering overhang weighs, and the stock drifts back toward year-ago lows. That scenario has not played out — and the STC today reflects a trader accepting that and moving on.

🔥 Near-Term Catalysts (Next 30–60 Days)

Q1 2026 Earnings — Early May 2026 (est. May 5–8)

The first meaningful near-term catalyst. Q1 2026 consensus estimates approximately $(1.10) per share loss with essentially no revenue (pre-commercial stage). The numbers themselves are not the story — the market will focus on:

• Pro-forma cash confirmation post-$345M offering: management should affirm $800M+ with runway through 2027 per BioSpace
• R&D burn rate guidance for the Phase 3 analytical period — Phase 3 data lock, statistical analysis, and potential pre-NDA meetings are all expense events in H2 2026 and 2027
• Color on EMBARQ-CSU primary analysis timeline — the primary endpoint is UAS7 change at Week 12, with the primary analysis conducted at Week 24. Any tightening of the readout window would be a significant catalyst
• Phase 2 PN enrollment/status update — topline in summer 2026 is a pipeline-expansion catalyst per Celldex IR

EAACI Congress 2026 — June 2026

A high-probability venue for additional barzolvolimab Phase 2 long-term extension data building on the EAACI 2025 76-week results. Further durability data could reinforce the Phase 3 setup.

🚀 Medium-Term Catalysts (Summer–Q4 2026)

Phase 2 Prurigo Nodularis Topline — Summer 2026 (Q3)

Enrollment is complete. PN is a $1B+ market opportunity currently led by Dupixent and represents barzolvolimab's first expansion beyond urticaria into the broader itch/inflammatory pathway. A positive read would extend the pipeline optionality thesis and could provide a stock catalyst independent of the CSU Phase 3. Per Celldex IR.

⚠️ EoE precedent matters: Barzolvolimab showed profound mast cell depletion (~71%) in eosinophilic esophagitis but failed on all clinical endpoints in August 2025 per Celldex IR. This disconnect between target engagement and symptom improvement is a relevant cautionary read-through for PN — the question is whether mast cells are the primary driver of itch and skin changes in PN the way they are in urticaria. The data will tell.

EMBARQ-CSU1 / CSU2 Topline — Q4 2026 (THE Event)

This is the entire thesis — and the binary that originally informed the bearish put purchase, now too far away to recover for the exiting trader. Two global Phase 3 trials, 1,939 patients total — the largest Phase 3 dataset in antihistamine-refractory CSU ever conducted per Celldex IR. The primary endpoint is change in UAS7 at Week 12, with the placebo-controlled period ending at Week 24.

Phase 2 performance benchmarks, all referenced in Celldex's AAAAI 2026 data releases:

• 51% complete response at 12 weeks (Phase 2)
• 71% complete response at 52 weeks (Phase 2 extension)
• 41% complete response 7 months after last dose (durability)

For comparison, AJMC analysis shows Dupixent and remibrutinib achieve 28–32% complete response in CSU — suggesting meaningful differentiation if Phase 3 bridges. But Phase 2 was open-label; the placebo response rate in refractory CSU can be 10–20%, compressing the observed delta vs placebo.

A clean win across both trials = 2027 BLA filing, potential 2028 PDUFA. A miss in either trial = significant equity destruction.

Phase 2 Atopic Dermatitis Topline — Late 2026

Enrollment complete. This readout will arrive alongside or shortly after the Phase 3 CSU data, adding another layer of binary risk to the Q4–Q1 period per Celldex IR AD initiation.

🏁 Competitive Landscape

The CSU treatment market has changed materially in the past 12 months:

• Dupixent (dupilumab) — FDA-approved for CSU in April 2025 per Springer Nature review
• Rynkrisa (remibrutinib, Novartis) — FDA-approved for CSU in September 2025, a BTK inhibitor offering an oral option
• Xolair (omalizumab) — remains the incumbent anti-IgE standard of care

Barzolvolimab is the only mechanism that directly depletes mast cells via KIT inhibition. If Phase 3 data holds, it enters a competitive but validated market with a potentially superior complete response profile. The global CSU therapeutics TAM is estimated at $3–5B by 2030 per AJMC, plus meaningful PN, AD, ColdU, and SD optionality.

---

🎲 Price Targets & Probabilities

Analyst consensus as of April 24, 2026 per Markets Daily:

• Consensus 12-month price target: $44.45–$53.91
• High target: $90.00 (Piper Sandler)
• Low target: $24.00
• Notable moves: Barclays Underweight → Overweight, PT $24 → $45; Wolfe Research Peer Perform → Outperform, $44 PT; Stifel Buy, PT raised to $68

Using the gamma structure, implied move data, and clinical catalyst analysis:

📈 Bull Case (30% probability)

Target: $55–$90

Clean dual-trial win in EMBARQ-CSU1 and CSU2 in Q4 2026, followed by a 2027 BLA filing. Positive Phase 2 PN data in summer 2026 adds pipeline optionality. Cash position above $800M absorbs the commercial-build ramp. Analyst targets converge on $68–$90 range. At $33.84 today, that represents +100% to +166% from current levels on a 12–18 month view. The Phase 2 data (51% CR, 71% at 52 weeks, durability signal) provides arguably the strongest clinical read-through ever produced in this disease category per Celldex's EAACI 2025 release.

Path there: Solid Q1 earnings with cash confirmation → PN Phase 2 positive in summer → EMBARQ-CSU readout hit in Q4 → stock rerates toward launch comps.

🎯 Base Case (40% probability)

Target: $35–$55 through Q3 2026, then binary reset

Between now and the Phase 3 readout, CLDX trades in a relatively tight range ($32–$45) as investors price in both the upside and the clinical risk. Gamma resistance at $35 acts as a near-term ceiling and the stock grinds higher on small data catalysts (EAACI, PN readout) but does not break out decisively until the CSU Phase 3 data arrives. Then it becomes a binary event either inflecting toward the bull case or the bear case.

📉 Bear Case (30% probability)

Target: $12–$20 on Phase 3 failure

A Phase 3 miss in one or both EMBARQ-CSU trials — particularly in the advanced-therapy-refractory subgroup — would likely result in a 40–55% single-day drawdown. The EoE Phase 2 failure (August 2025) provides a sobering precedent that profound mast cell depletion does not always translate to clinical benefit. The company has cash to survive and advance other programs, but the $2.5B valuation premium above cash is almost entirely barzolvolimab-in-CSU.

Why the bear case failed for the put buyer: The trader who bought the $27 puts was positioning for this bear scenario to materialize before December 2026. With the stock now at $33.84 and momentum bullish, that thesis needs a dramatic reversal to recover — which is precisely why they are exiting today rather than waiting.

---

💡 Trading Ideas

🛡️ Conservative: Hold Existing Positions Through Q1 Earnings, Reassess After

Play: If you own CLDX stock or have long call exposure, stay positioned through the early May Q1 earnings report but use the $35 gamma resistance as your near-term upside gauge.

Why this works:

• 📅 Q1 earnings is a low-risk catalyst: For a pre-revenue biotech, earnings is mostly a cash confirmation event. If management reiterates $800M+ cash and runway through 2027, stock should hold and potentially nudge higher
• 🎯 $32 support is solid: Three layers of support converge near $32 — gamma, post-offering behavioral anchor at $29–$30, and the KIT-resistance structural floor
• ⚠️ Position size matters: CLDX is a binary biotech. Size any position so that a 40–50% drawdown (Phase 3 failure scenario) does not materially impair your overall portfolio

Risk management: Set a mental alert if stock breaks below $30 (below the offering price with conviction), as that signals something has changed in institutional sentiment.

Risk level: Moderate | Skill level: Intermediate

⚖️ Balanced: Sell Cash-Secured Put Below Offering Price as Income (After Earnings Clarity)

Play: After Q1 earnings (expected early May), consider selling the $29 or $30 strike put expiring September or December 2026. You collect premium while positioning to buy CLDX at or below the April offering price if the stock corrects.

Why this works:

• 💰 The $29 strike has natural support: The April offering was done at $29.00 by major institutions. Below that price is where offering buyers and underwriters (Leerink, TD Cowen, Guggenheim, Cantor) become natural buyers per April 6 offering release
• 📊 Expected setup: With CLDX at $33.84, a September $29 put might trade for $2.50–$4.00 depending on IV. That gives you a $25–$26.50 effective cost basis if assigned — roughly 20–25% below current levels and close to the $800M cash implied floor
• 🔄 You're taking the opposite side of the trade that just failed: The put buyer who just closed out was wrong on direction. Selling the put (collecting premium for being willing to own CLDX at $29) is the inverse bet — and a structurally more favorable one given where the stock is now

Position sizing: Sell only as many puts as you have cash to cover assignment. Each contract = obligation to buy 100 shares at $29, so $2,900 per contract in reserved cash.

Risk management: If CLDX breaks below $26 heading into the Phase 3 readout, the market may be pricing in early leaks of negative data. Plan to close if stock closes below $26 on elevated volume.

Risk level: Moderate (obligation to buy stock at $29 if assigned, but at an attractive basis relative to current price and analyst targets) | Skill level: Intermediate

🚀 Aggressive: Long Call Spread Targeting EMBARQ-CSU Data Window (Advanced)

Play: Buy the $37 call / sell the $50 call, December 2026 expiration. This is a debit spread that profits if CLDX rallies materially into or after the Phase 3 CSU readout.

Structure example:

• Buy Dec 2026 $37 calls (roughly $4–$6 estimated)
• Sell Dec 2026 $50 calls (roughly $1–$2 estimated)
• Net debit: approximately $3–$5 per spread
• Max profit: $13 per spread ($50 – $37) if stock above $50 at December expiration
• Breakeven: ~$40–$42 (spread debit + $37 strike)

Why this could work:

• 📅 December expiration brackets the Phase 3 readout — the data is expected Q4 2026, likely October–November. December expiration gives two to four weeks for the initial reaction to play out
• 🎯 $50 short strike sits just below the Stifel $68 and Barclays $45 targets — defined risk on a move that various analysts already see as achievable per Markets Daily
• 💸 Defined maximum loss: Unlike the put buyer who just stopped out, a call spread has a fixed maximum loss (the premium paid). You know the worst case going in.

CRITICAL REQUIREMENTS — Do not attempt unless:

• ✅ You fully understand vertical spreads and have traded them before
• ✅ You can afford to lose 100% of the debit — a Phase 3 miss leaves these calls worthless
• ✅ You accept this is a speculative position, not a core holding
• ✅ You will not size this position to where a total loss impairs your portfolio materially
• ✅ You understand that biotech binary events have genuine 30–40% failure probability even with strong Phase 2 data

Risk level: HIGH | Skill level: Advanced only | Probability of profit: 30–35% (aligned with bull case probability)

---

⚠️ Risk Factors

Know what you own before you trade it:

• ☢️ Phase 3 binary risk is dominant: EMBARQ-CSU1 and CSU2 topline in Q4 2026 is a 40–60% point-in-time success/failure event. Phase 2 to Phase 3 translation rates in immunology are historically around 50–60%, and placebo response in refractory CSU can compress observed treatment effects. A miss in either trial would likely erase 40–55% of market cap in a single session. This is not a risk that can be diversified away — it is the entire trade.

• 🔴 EoE Phase 2 failure is an unresolved warning signal: In August 2025, barzolvolimab achieved 71% mast cell depletion in EoE patients but showed no clinical benefit on symptom scores, endoscopy, or histology per Celldex IR. The CSU disease biology is more tightly linked to mast cells than EoE, which makes the Phase 2 CSU data arguably more reliable as a read-through. But the EoE miss is a legitimate reminder that mechanism engagement and clinical benefit are not the same thing. This was precisely the risk the exiting put buyer was betting on — and it is still a real risk for the Phase 3.

• 💸 Dilution has happened before and could happen again: The April 2026 offering at $29.00 was the third dilutive financing in three years per Stocktitan. Annual cash burn is approaching $300M. Even with $800M+ pro-forma cash, the company may need to raise again — either pre-commercialization if Phase 3 succeeds (commercial-build capital) or post-failure if the pipeline needs repositioning.

• 🏥 Competitive crowding reduces peak sales potential: Dupixent's April 2025 CSU approval and remibrutinib's September 2025 CSU approval per Springer Nature review mean barzolvolimab would enter as the third advanced-therapy option, not the first. Payers may require prior therapy failures with Xolair and/or Dupixent. Oral remibrutinib offers a route-of-administration advantage for patients. Second-line positioning in a crowded market compresses the addressable population and peak sales estimates.

• 📉 Stock is trading at a significant premium to cash: With pro-forma cash above $800M and ~78M shares at $33.84, the market cap is roughly $2.6B. The market is paying ~$1.8B above cash for the clinical pipeline — essentially a single-asset premium on barzolvolimab-in-CSU. Any clinical setback reprices that premium sharply.

• 🌍 Macro and XBI sector risk: The small/mid biotech complex carries high beta to broader risk-off moves. A broad market sell-off, rising interest rates (which compress DCF values of unprofitable growth companies), or a sector-wide clinical disappointment could pressure CLDX regardless of its own newsflow. The XBI ETF has historically dropped 25–40% in macro risk-off episodes, dragging binary biotechs with it.

• 💊 KIT inhibition safety profile: Long-term neutropenia and pigmentation changes (KIT signaling is involved in melanocyte biology) will be a key focus of the BLA review. Any emerging safety signal in the 1,939-patient Phase 3 dataset could complicate or delay FDA approval even if the primary endpoint is met.

---

🎯 The Bottom Line

Real talk: A trader who made a bearish bet on CLDX — buying $27 strike December puts to position for a stock decline — has been proven wrong. CLDX has run from roughly $29–$30 at the time of the April offering to $33.84 today, putting those puts 25% out of the money. Today's $1.1M STC trade is that trader salvaging what they can ($7.40/contract) before time decay and continued stock strength erode the position further.

This is a bear stopping out, not a bull cashing in.

What this trade tells us:

• 🐻 Someone was structurally bearish on CLDX — and is now exiting that bet. The $27 put position was a calculated bearish thesis, likely anchored on the April offering overhang, the EoE Phase 2 failure precedent, and concern about Phase 3 translation. That thesis has not materialized in time, and the trader is moving on.
• 📈 The stock's resilience is itself a signal. A $345M offering at $29 typically creates months of overhang. That CLDX has already traded through it by +17% in three weeks reflects genuine institutional demand, not just passive drift.
• ⚖️ Neutral-to-slightly-bullish repositioning: The STC removes a bearish position from the market. It is not a new bullish bet, but it is one less active bear. Vol/OI above 1 confirms this is a full exit, not a partial trim.
• 📊 Gamma structure is constructive: Net bullish GEX bias, $35 as the near-term ceiling, and $32–$29 as a layered support floor all point to a stock that the options market is treating as orderly and well-supported at current levels

If you own CLDX:

• ✅ Hold through Q1 earnings — cash confirmation is a low-risk catalyst
• 🔵 Treat $32 and $29 as your key support levels — gamma and behavioral support both anchor here
• 📊 Watch for $35 resistance — a clean break above $35 opens the path to $37–$40 in the near term
• 🎯 Scale position to account for binary risk — even if you are bullish on the clinical data, size the position so a 40–50% drawdown is survivable

If you are watching from the sidelines:

• ⏰ Early May Q1 earnings is your first signal check — cash runway reaffirmation and any update on EMBARQ-CSU primary analysis timing
• 🌞 Summer 2026 PN readout is the first real clinical test — a positive Phase 2 PN result would validate that the mast-cell mechanism works outside of urticaria and lift the stock ahead of the Phase 3 CSU data
• ⚠️ The Phase 3 is the trade-defining event — every position you take in CLDX between now and Q4 2026 is fundamentally a bet on that readout. Be intentional about it.

Mark your calendar — Key dates:

• 📅 Early May 2026 — Q1 2026 earnings (cash, burn rate, EMBARQ-CSU timeline commentary)
• 📅 June 2026 — EAACI Congress (potential Phase 2 extension data presentation)
• 📅 Summer 2026 — Phase 2 Prurigo Nodularis topline per Celldex IR
• 📅 Q4 2026 — EMBARQ-CSU1 and EMBARQ-CSU2 Phase 3 topline (the defining event)
• 📅 Late 2026 — Phase 2 Atopic Dermatitis topline per Celldex IR AD initiation
• 📅 2027 — Potential BLA filing if Phase 3 succeeds; potential PDUFA date in 2028

Final verdict: CLDX is a textbook catalyst-driven biotech trade. Today's tape confirms that even bears who saw the risk in this name are now capitulating — not because the Phase 3 risk has gone away, but because the stock has moved decisively against the bearish thesis. The Phase 2 data for barzolvolimab in CSU — 51% complete response at 12 weeks, 71% at 52 weeks, durability signal seven months off-drug per Celldex AAAAI 2026 data release — is genuinely differentiated versus Dupixent and remibrutinib class benchmarks per AJMC. Enrollment completed six months early with 1,939 patients in the largest Phase 3 ever in antihistamine-refractory CSU per Celldex IR. The cash position is strong. The analysts are upgrading.

But make no mistake — this is a binary. Every dollar you put in CLDX today is exposed to a 30–40% probability of a 40–55% drawdown in Q4 2026 if the Phase 3 data disappoints. The EoE failure precedent is real. The put buyer who just closed out understood the downside risk — they just got the timing and direction wrong. The question for you is whether the remaining upside — potentially $55–$90 in a Phase 3 success scenario versus $12–$20 in a failure — justifies the position size you are considering.

Know the risk. Respect the binary. Size accordingly.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. The options strategies described — including selling puts, buying call spreads, and holding long equity positions in clinical-stage biotechs — can result in the partial or total loss of capital. Clinical-stage biotechnology investments carry additional risks including clinical trial failure, regulatory uncertainty, and equity dilution. The Z-score and unusual activity metrics reflect statistical unusualness relative to recent CLDX options activity — they do not imply the referenced trades will be profitable or that you should replicate them. Past performance does not guarantee future results. Always consult a licensed financial advisor and conduct your own due diligence before making investment decisions.